Latest Director Appointments News

Noble Helium Limited has announced a sweeping board and executive reshuffle following pressure from major shareholders, signaling a strategic reset aimed at strengthening its financial footing and advancing its Tanzanian helium projects.

Cycliq Group Limited reported an 18% revenue increase to $2.9 million for the half-year ending December 2024, driven by higher transaction values and a revamped marketing strategy, despite a modest net loss of $211,214.

Sigma Healthcare has completed its acquisition of Chemist Warehouse, issuing new shares and cash to former shareholders and appointing a refreshed board to steer the merged entity forward.

Summit Minerals appoints Dr. Matthew Cobb as CEO to accelerate development of its Equador Niobium and Rare Earth Elements Project in Brazil, while reshuffling leadership to bolster operational focus.

Redivium Limited remains suspended from ASX trading following a failed entitlement offer and key director resignations, raising fresh doubts about its financial viability and governance.

Pacific Nickel Mines Limited has paused its Kolosori Nickel Project due to operational setbacks and a challenging nickel price environment, entering voluntary suspension while negotiating critical financing with Glencore.

Corella Resources reports promising rare earth element drilling results at its Tampu Project alongside significant board and management changes, while facing tight cash reserves.

Papyrus Australia has taken significant strides in Q4 2024, signing a joint venture terms sheet in Vietnam, appointing new board members, and securing R&D tax incentives, positioning itself for expanded commercialization.

Western Yilgarn NL reports encouraging exploration results at its Ida Holmes Project, alongside a successful capital raising and strategic board changes, setting the stage for accelerated development in 2025.

DMC Mining Limited moves closer to ASX re-admission as Guinea reopens its cadastral licensing system, enabling imminent exploration licenses for key projects. The company also strengthens its leadership team and secures additional financing to support upcoming operations.

Genetic Signatures reported a robust 190% increase in quarterly sales to $3.8 million, driven by strong respiratory testing demand in Australia and strategic UK deployments. Despite longer US sales cycles, the company maintains a solid $40.8 million cash position and advances R&D on its 3base® platform.

Dubber Corporation Limited reports steady revenue growth and cost reductions in Q2 FY25, alongside a refreshed board and strategic initiatives aimed at achieving operating cashflow breakeven by year-end.